Egfr Inhibitors Induced Skin Disorders Market

DelveInsight’s ‘EGFR Inhibitors-Induced Skin Disorders-Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the EGFR Inhibitors-Induced Skin Disorders historical and forecasted epidemiology as well as the EGFR Inhibitors-Induced Skin Disorders market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The EGFR Inhibitors-Induced Skin Disorders market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM EGFR Inhibitors-Induced Skin Disorders market size from 2021 to 2030. The Report also covers current EGFR Inhibitors-Induced Skin Disorders treatment practice, market drivers, market barriers, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

EGFR Inhibitors-Induced Skin Disorders Disease Understanding

EGFR Inhibitors-Induced Skin Disorders Overview

The epidermal growth factor receptor (EGFR) is a transmembrane protein that regulates multiple cellular processes. The EGFR inhibitor is a class of targeted antitumor agents designed to bind to the EGFR, thereby preventing its activity. The US FDA, the EMA, and the PMDA have approved several drugs in this class, and associated side effects have also been noticed.


The most common side effects of EGFR-targeted therapies are dermatologic toxicities. EGFR inhibitor-mediated dermatologic side-effects include an acneiform skin rash, hyperpigmentation, xerotic skin, pruritus, skin fissures, nail changes, and disorders of mucous membranes, eyes, and hair.


It is characterized by red papules and/or pustules on the face, chest, abdomen, or thighs; dry and scaly skin; fissures; hyperpigmentation; itchy skin eczema; erythema around several fingernails and toenails and other symptoms observed after anti-EGFR therapy.


EGFR Inhibitors-Induced Skin Disorders Diagnosis

The initial evaluation of a patient with EGFR inhibitors-induced skin disorders includes medical history, physical examination, and clinical symptoms, including the affected area. The lack of clinical practice guidelines for diagnosis, grading, and management is the key unmet need of the EGFR inhibitors-induced skin disorders market.

Continued in the report…..


EGFR Inhibitors-Induced Skin Disorders Treatment

EGFR Inhibitors-Induced Skin Disorders is usually a self‐limiting disease with a clinical course that may last from months to years. Treatment is best individualized according to the type and the extent of the skin lesions. Topical antibiotic treatment with erythromycin, metronidazole, or nadifloxacin twice-daily has been recommended for early-stage, and low-grade papulopustular skin reactions cream or lotion preparations is preferred to take advantage of an additional moisturization effect. Topical hydrocortisone 1% cream or topical calcineurin inhibitors, such as pimecrolimus, have been reported to be effective. Oral tetracyclines, such as doxycycline or minocycline, reduce the severity and extent of the acneiform eruption. Paronychia is treated with daily antiseptic baths to avoid bacterial superinfection.


Current treatment for dermatological toxicity associated with EGFR inhibitors is limited to oatmeal baths, topical protection measures, avoidance of skin drying activities like hot-showers, and mild antibiotics. The choice of treatment depends on the individual patient’s circumstances, especially the severity of the EGFR Inhibitors-Induced Skin Disorders and the presence of comorbidities.

Continued in the report…..

EGFR Inhibitors-Induced Skin Disorders Epidemiology  

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Number of Cases on EGFR inhibitors by Cancer Type, and Total Cases of EGFR Inhibitors-induced Skin Disorders scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.


Key Findings

  • The total number of cases of EGFR Inhibitors-induced Skin Disorders in the 7MM was 106,119 in 2020, which is likely to increase by 2030 at a CAGR of 4.37% for the study period (2018–2030).
  • In 2020, the total number of cases of cancer patients on EGFR inhibitors in the US was estimated to be 57,541, which is likely to increase by 2030 at a CAGR of 5.66% for the study period (2018–2030).
  • The total number of cases of EGFR Inhibitors-induced Skin Disorders in the US was 37,463 in 2020.
  • In 2020, the total number of cancer patients on EGFR inhibitor therapy in the US was highest for NSCLC (28,425), followed by colorectal cancers and breast cancer. Whereas the total cases of EGFR Inhibitors-induced Skin Disorders in the US in 2020 were highest in colorectal cancer (21,453), followed by NSCLC and Head and Neck cancer.
  • Among the EU-5 countries, in 2020, the highest cases of EGFR Inhibitors-induced Skin Disorders were found in Germany (12,010), followed by France (9,632) and Italy (9,330); while Spain (7,716) accounted for the least number of cases.
  • Japan accounted for 19.89% (21,102 cases) of total cases of EGFR Inhibitors-induced Skin Disorders among 7MM in 2020. These cases are expected to rise by 2030 at a CAGR of 5.12%.

EGFR Inhibitors-Induced Skin Disorders Epidemiology

The epidemiology segment also provides the EGFR Inhibitors-Induced Skin Disorders epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

EGFR Inhibitors-Induced Skin Disorders Drug Chapters

EGFR Inhibitors-Induced Skin Disorders Emerging Drugs


Imsidolimab (ANB019): AnaptysBio Inc.

ANB019 is an antibody, being developed by AnaptysBio Inc that inhibits the function of the interleukin-36-receptor or IL-36R. The role of the IL-36RA is to dampen the inflammatory effects of IL-36 alpha, IL-36 beta, and IL-36 gamma. The company has completed a phase I trial of ANB019 in healthy volunteers under an approved Clinical Trials Network (CTN), has received clearance of a Clinical Trial Application (CTA) filing to the Medicines and Healthcare products Regulatory Agency (MHRA), and an IND filing with the FDA. Currently, ANB019 is being investigated in a phase II trial called EMERGE for treatment of EGFRi/MEKi-mediated skin toxicity, of which interim top-line data is anticipated at the end of 2021. The safety and efficacy of ANB019 were also evaluated in a phase I trial, 36 patients with EGFR Inhibitors-Induced Skin Disorders were studied. ANB019 was well-tolerated by all subjects, and no dose-limiting toxicities were observed.

Products detail in the report…


AC-701 Topical Gel 0.3%: TWi Pharmaceuticals

AC-701 is a small molecule anti-inflammatory modulator being developed by TWi Pharmaceuticals. It works by inhibiting the release of IL-1α and IL-8 cytokines. This inhibition can be used to treat immune-related dermal diseases. Currently, AC-701 is being developed to treat target cancer-therapy-induced skin rash and Rosacea. AC-701 is in phase II of the clinical trial to evaluate the prophylactic efficacy of topical AC-701 in subjects with skin rash associated with EGFRI therapy. AC-701 is being developed for skin rash brought on by targeted treatment of lung and colon cancers.

Products detail in the report…

List to be continued in the report…

EGFR Inhibitors-Induced Skin Disorders Market Outlook

Inhibitors of the epidermal growth factor receptor (EGFR) are used in a growing range of tumor types to improve clinical outcomes. EGFR may be inhibited with anti-EGFR-specific monoclonal antibodies or small-molecule tyrosine kinase inhibitors. Dermatologic toxic effects are the most common side-effects associated with anti-EGFR therapy.


The treatment of EGFR inhibitor-related skin reactions is not standardized, and accounts in the literature are based on local practice and mainly derived from personal, albeit extensive, experience. Currently, there is no approved therapy specific for anti-EGFR induced skin diseases in the US, EU, and Japan. The off-label therapeutic options used for anti-EGFR induced skin diseases are sunscreen, emollients and soap substitutes, antibiotics, antihistamines, topical steroids, and cosmetics.


In contrast to acne vulgaris, topical antibiotic treatment with erythromycin, metronidazole, or nadifloxacin twice daily is recommended for early-stage and low-grade papulopustular skin reactions. Cream or lotion preparations are preferred to take advantage of an additional moisturization effect. Fissures are treated topically with propylene glycol 50%. For grade 3 rash, oral corticosteroids (methylprednisolone dose pack or prednisone 0.5 mg/kg for 7 days) are also considered to be beneficial.


The market has a critical unmet need for approved therapies specific to EGFR inhibitor-induced skin disorders. The treatment is mainly based on off-label therapies with limited safety and efficacy data. Corticosteroid use is also often limited due to their toxicity on long-term use. The patient population of cancers and EGFR inhibitor utilization is expected to increase throughout the forecast period (2021–2030). These may contribute to the rise of the patient population of EGFR inhibitor-induced skin disorders. With this and the expected launch of emerging therapy Imsidolimab (ANB019), the market is expected to show a significant boost during the forecast period.

Continued in the report…..


Key Findings

  • The market size of EGFR Inhibitors-induced Skin Disorders in the 7MM was estimated to be USD 57 million in 2020, and with the expected approval of Imsidolimab (ANB019); and with an increased incidence of cancers with EGFR mutation, the market is expected to upsurge by 2030 at a CAGR of 18.25% for the study period of 2018–2030.
  • The United States holds the largest market share of the EGFR Inhibitors-induced Skin Disorders among the 7MM countries, which accounts for 49.59% (USD 28 million) of the total 7MM market, in 2020.
  • Among the EU-5 countries, Germany (USD 5 million) had the highest market share, followed by France (USD 4 million) and Italy (USD 4 million), in 2020.
  • Japan holds the second-largest share of the 7MM EGFR Inhibitors-induced Skin Disorders market with a market size of USD 9 million in 2020, which is expected to rise by 2030 at a CAGR of 17.05% for the study period of 2018–2030.
  • EGFR Inhibitors-Induced Skin Disorders' current treatment market is limited to topical steroid cream or ointment, local and systemic therapies, and others.
  • Imsidolimab (ANB019) is expected to reach the market by 2025, generating a market size of USD 3 million in the launch year. As the current market is mainly based on off-label therapies, it might capture a large market share of current therapies by 2030.


The United States Market Outlook

This section provides the total EGFR Inhibitors-Induced Skin Disorders market size and market size by therapies in the United States.


EU-5 Market Outlook

The total EGFR Inhibitors-Induced Skin Disorders market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.


Japan Market Outlook

The total EGFR Inhibitors-Induced Skin Disorders market size and market size by therapies in Japan are provided.

EGFR Inhibitors-Induced Skin Disorders Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the EGFR Inhibitors-Induced Skin Disorders market or expected to get launched in the market during the study period 2018–2030. The analysis covers the EGFR Inhibitors-Induced Skin Disorders market uptake by drugs; patient uptake by therapies; and sales of each drug. 


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

EGFR Inhibitors-Induced Skin Disorders Development Activities

The report provides insights into different therapeutic candidates in the phase II stage. It also analyzes key players involved in developing targeted therapeutics.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for EGFR Inhibitors-Induced Skin Disorders emerging therapies.

Reimbursement Scenario in EGFR Inhibitors-Induced Skin Disorders

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive market Intelligence analysis of the EGFR Inhibitors-Induced Skin Disorders market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of EGFR Inhibitors-Induced Skin Disorders, explaining side effects of EGFR inhibitor treatment, mechanisms underlying EGFR inhibitor-induced cutaneous disorders, various diagnostic approaches, and currently available therapies.
  • Comprehensive insight has been provided into the EGFR Inhibitors-Induced Skin Disorders epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for EGFR Inhibitors-Induced Skin Disorders is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the EGFR Inhibitors-Induced Skin Disorders market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM EGFR Inhibitors-Induced Skin Disorders market.

Report Highlights

  • The robust pipeline with novel MOA and oral ROA, increasing incidence, effectiveness of drugs as both mono and combination therapy will positively drive the EGFR Inhibitors-Induced Skin Disorders market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence EGFR Inhibitors-Induced Skin Disorders R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for EGFR Inhibitors-Induced Skin Disorders. The launch of emerging therapies will significantly impact the EGFR Inhibitors-Induced Skin Disorders market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

EGFR Inhibitors-Induced Skin Disorders Report Insights

  • Patient Population
  • Therapeutic Approaches
  • EGFR Inhibitors-Induced Skin Disorders Pipeline Analysis
  • EGFR Inhibitors-Induced Skin Disorders Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

EGFR Inhibitors-Induced Skin Disorders Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • EGFR Inhibitors-Induced Skin Disorders Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

EGFR Inhibitors-Induced Skin Disorders Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Key Questions

Market Insights:

  • What was the EGFR Inhibitors-Induced Skin Disorders market share (%) distribution in 2018 and how it would look like in 2030?
  • What would be the EGFR Inhibitors-Induced Skin Disorders total market size as well as market size by therapies across the 7MM during the forecast period (2021–2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest EGFR Inhibitors-Induced Skin Disorders market size during the forecast period (2021–2030)?
  • At what CAGR, the EGFR Inhibitors-Induced Skin Disordersmarket is expected to grow at the 7MM level during the forecast period (2021–2030)?
  • What would be the EGFR Inhibitors-Induced Skin Disorders market outlook across the 7MM during the forecast period (2021–2030)?
  • What would be the EGFR Inhibitors-Induced Skin Disorders market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burdens, and unmet needs of EGFR Inhibitors-Induced Skin Disorders?
  • What is the historical EGFR Inhibitors-Induced Skin Disorders patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of EGFR Inhibitors-Induced Skin Disorders at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to EGFR Inhibitors-Induced Skin Disorders?
  • Out of the above-mentioned countries, which country would have the highest population of EGFR Inhibitors-Induced Skin Disorders during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of EGFR Inhibitors-Induced Skin Disorders along with the approved therapy?
  • What are the current treatment guidelines for the treatment of EGFR Inhibitors-Induced Skin Disorders in the US and Europe?
  • What are the EGFR Inhibitors-Induced Skin Disorders marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of EGFR Inhibitors-Induced Skin Disorders?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of EGFR Inhibitors-Induced Skin Disorders?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the EGFR Inhibitors-Induced Skin Disorders therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for EGFR Inhibitors-Induced Skin Disorders and their status?
  • What are the key designations that have been granted for the emerging therapies for EGFR Inhibitors-Induced Skin Disorders?
  • What are the 7MM historical and forecasted market of EGFR Inhibitors-Induced Skin Disorders?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving EGFR Inhibitors-Induced Skin Disorders.
  • To understand the future market competition in the EGFR Inhibitors-Induced Skin Disorders market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for EGFR Inhibitors-Induced Skin Disorders in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the EGFR Inhibitors-Induced Skin Disorders market.
  • To understand the future market competition in the EGFR Inhibitors-Induced Skin Disorders market.

1. Key Insights

2. Report Introduction

3. EGFR Inhibitors-induced Skin Disorders Market Overview at a Glance

3.1. Market Share (%) Distribution of EGFR Inhibitors-induced Skin Disorders in 2018

3.2. Market Share (%) Distribution of EGFR Inhibitors-induced Skin Disorders in 2030

4. Executive Summary of EGFR Inhibitors-Induced Skin Disorders

5. Disease Background and Overview

5.1. Introduction

5.2. Side Effects of EGFR Inhibitor Treatment

5.3. Mechanisms Underlying EGFR Inhibitors Induced Cutaneous Disorders

5.3.1. Skin inflammation, or rash and folliculitis

5.3.2. Nail and periungual toxicity

5.3.3. Barrier defect/xerosis

5.3.4. Antimicrobial defense/infections

5.3.5. Hair alterations

5.4. Diagnosis

5.4.1. Differential Diagnosis of EGFR-induced rash

5.4.2. Diagnosis and patient education of drug-induced hair disorders

5.4.3. Diagnosis of xerosis cutis

5.5. Treatment

5.5.1. Treatment of acneiform rash

5.5.2. Treatment of nail changes

5.5.3. Treatment of xerotic and eczematous skin

5.5.4. Treatment of pruritus/itching

5.5.5. Treatment of fissures

5.6. Treatment Algorithm

5.7. Management Guidelines and Treatment Recommendations

5.7.1. General treatment recommendations

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Methodology of Epidemiology

6.2.1. NSCLC

6.2.2. Colorectal Cancer

6.2.3. Pancreatic Cancer

6.2.4. Head and Neck Cancer

6.2.5. Breast Cancer

6.3. Total Cases of Cancer on EGFR Inhibitors in the 7MM

6.4. Total Cases on EGFR Inhibitors in the 7MM

6.5. Total Cases of EGFR Induced Skin Disorders in the 7MM

6.6. Total Cases of EGFR Induced Skin Disorders by Cancer Type in the 7MM

6.7. Epidemiology of EGFR Inhibitors-induced Skin Disorders

6.7.1. Assumptions and Rationale for NSCLC

6.7.2. Assumptions and Rationale for Colorectal Cancer

6.7.3. Assumptions and Rationale for Pancreatic Cancer, Breast Cancer, and Head and Neck Cancer

6.8. The United States

6.8.1. Total Number of Cases on EGFR inhibitors by Cancer Type in the US

6.8.2. Total Cases of EGFR Inhibitors-induced Skin Disorders in the US

6.9. EU5

6.9.1. Germany

6.9.1.1. Total Number of Cases on EGFR inhibitors by Cancer Type in Germany

6.9.1.2. Total Cases of EGFR Inhibitors-induced Skin Disorders in Germany

6.9.2. France

6.9.2.1. Total Number of Cases on EGFR inhibitors by Cancer Type in France

6.9.2.2. Total Cases of EGFR Inhibitors-induced Skin Disorders in France

6.9.3. Italy

6.9.3.1. Total Number of Cases on EGFR inhibitors by Cancer Type in Italy

6.9.3.2. Total Cases of EGFR Inhibitors-induced Skin Disorders in Italy

6.9.4. Spain

6.9.4.1. Total Number of Cases on EGFR inhibitors by Cancer Type in Spain

6.9.4.2. Total Cases of EGFR Inhibitors-induced Skin Disorders in Spain

6.9.5. The United Kingdom

6.9.5.1. Total Number of Cases on EGFR inhibitors by Cancer Type in the United Kingdom

6.9.5.2. Total Cases of EGFR Inhibitors-induced Skin Disorders in the United Kingdom

6.10. Japan

6.10.1. Total Number of Cases on EGFR inhibitors by Cancer Type in Japan

6.10.2. Total Cases of EGFR Inhibitors-induced Skin Disorders in Japan

7. Patient Journey

8. Emerging Therapies

8.1. Key Cross Competition

8.2. AC-701 Topical Gel 0.3%: TWi Pharmaceuticals

8.2.1. Drug Description

8.2.2. Other Developmental Activities

8.2.3. Clinical Development

8.2.4. Clinical Trials Information

8.2.5. Product Profile

8.3. ATR-04: Azitra Inc.

8.3.1. Drug Description

8.3.2. Other Developmental Activities

8.3.3. Clinical Development

8.3.4. Clinical Trials Information

8.3.5. Product Profile

8.4. Imsidolimab (ANB019): AnaptysBio Inc.

8.4.1. Drug Description

8.4.2. Other Developmental Activities

8.4.3. Clinical Development

8.4.4. Clinical Trials Information

8.4.5. Safety and Efficacy

8.4.6. Product Profile

8.5. LUT014: Lutris Pharma Ltd.

8.5.1. Drug Description

8.5.2. Other Developmental Activities

8.5.3. Clinical Development

8.5.4. Clinical Trials Information

8.5.5. Product Profile

8.6. HT-001/WEG232 (Aprepitant): Hoth Therapeutics

8.6.1. Drug Description

8.6.2. Other Developmental Activities

8.6.3. Product Profile

9. EGFR Inhibitors-induced Skin Disorders: Seven Major Market Analysis

9.1. Key Findings

9.2. Methodology of EGFR Inhibitors-induced Skin Disorders Market

9.3. Market Size of EGFR Inhibitors-induced Skin Disorders in the 7MM

9.4. Market Size of EGFR Inhibitors-induced Skin Disorders by Therapies

9.5. Key Market Forecast Assumptions

9.6. 7MM Market Outlook

9.7. United States Market Size

9.7.1. Total Market Size of EGFR Inhibitors-Induced Skin Disorders in the United States

9.7.2. Market Size of EGFR Inhibitors-Induced Skin Disorders by Therapies in the United States

9.8. EU-5 Market Size

9.8.1. Germany

9.8.1.1. Total Market size of EGFR Inhibitors-Induced Skin Disorders in Germany

9.8.1.2. Market Size of EGFR Inhibitors-Induced Skin Disorders by Therapies in Germany

9.8.2. France

9.8.2.1. Total Market size of EGFR Inhibitors-Induced Skin Disorders in France

9.8.2.2. Market Size of EGFR Inhibitors-Induced Skin Disorders by Therapies in France

9.8.3. Italy

9.8.3.1. Total Market size of EGFR Inhibitors-Induced Skin Disorders in Italy

9.8.3.2. Market Size of EGFR Inhibitors-Induced Skin Disorders by Therapies in Italy

9.8.4. Spain

9.8.4.1. Total Market size of EGFR Inhibitors-Induced Skin Disorders in Spain

9.8.4.2. Market Size of EGFR Inhibitors-Induced Skin Disorders by Therapies in Spain

9.8.5. United Kingdom

9.8.5.1. Total Market size of EGFR Inhibitors-Induced Skin Disorders in the United Kingdom

9.8.5.2. Market Size of EGFR Inhibitors-Induced Skin Disorders by Therapies in the United Kingdom

9.9. Japan

9.9.1. Total Market size of EGFR Inhibitors-Induced Skin Disorders in Japan

9.9.2. Market Size of EGFR Inhibitors-Induced Skin Disorders by Therapies in Japan

10. Market Drivers

11. Market Barriers

12. SWOT Analysis

13. Unmet Needs

14. Appendix

14.1. Bibliography

14.2. Report Methodology

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

List of Table

Table 1: Summary of EGFR Inhibitors-induced Skin Disorders, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Summary of the different forms of cutaneous toxicities induced by epidermal growth factor receptor (EGFR)-targeted agents

Table 3: The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 grading scale (general and specific for acneiform rash)

Table 4: Diagnostic approach to patients with xerosis cutis

Table 5: Dermatologic toxicity management: papulopustular eruptions

Table 6: General recommendations for prophylaxis while receiving anti-EGFR inhibitor treatment: paronychia

Table 7: Dermatologic toxicity management

Table 8: Stage- and grade-specific treatment of skin reactions

Table 9: Treatments that should be avoided

Table 10: Total Cases of Cancer on EGFR Inhibitors in the 7MM (2018–2030)

Table 11: Total Cases on EGFR Inhibitors in the 7MM (2018–2030)

Table 12: Total Cases of EGFR Induced Skin Disorders in the 7MM (2018–2030)

Table 13: Total Cases of EGFR Induced Skin Disorders by Cancer Type in the 7MM (2018–2030)

Table 14: EGFR inhibitors for NSCLC

Table 15: Emerging EGFR inhibitors for NSCLC and their expected launch years

Table 16: EGFR inhibitors for NSCLC and their skin disorder-specific adverse events, continued…

Table 17: EGFR inhibitors for NSCLC and their skin disorder-specific adverse events

Table 18: EGFR inhibitors for metastatic colorectal cancer

Table 19: EGFR inhibitors for colorectal cancer and their skin disorder-specific adverse events

Table 20: EGFR inhibitors for Pancreatic, Head and Neck and Breast Cancers

Table 21: EGFR inhibitors for pancreatic cancer and their skin disorder-specific adverse events

Table 22: EGFR inhibitors for head and neck cancer and their skin disorder-specific adverse events

Table 23: EGFR inhibitors for breast cancer and their skin disorder-specific adverse events

Table 24: EGFR inhibitors Patent Expiry

Table 25: Total Number of Cases on EGFR inhibitors by Cancer Type in the United States (2018–2030)

Table 26: Total Cases of EGFR Inhibitors-induced Skin Disorders in the United States (2018–2030)

Table 27: Total Number of Cases on EGFR inhibitors by Cancer Type in Germany (2018–2030)

Table 28: Total Cases of EGFR Inhibitors-induced Skin Disorders in Germany (2018–2030)

Table 29: Total Number of Cases on EGFR inhibitors by Cancer Type in France (2018–2030)

Table 30: Total Cases of EGFR Inhibitors-induced Skin Disorders in France (2018–2030)

Table 31: Total Number of Cases on EGFR inhibitors by Cancer Type in Italy (2018–2030)

Table 32: Total Cases of EGFR Inhibitors-induced Skin Disorders in Italy (2018–2030)

Table 33: Total Number of Cases on EGFR inhibitors by Cancer Type in Spain (2018–2030)

Table 34: Total Cases of EGFR Inhibitors-induced Skin Disorders in Spain (2018–2030)

Table 35: Total Number of Cases on EGFR inhibitors by Cancer Type in the UK (2018–2030)

Table 36: Total Cases of EGFR Inhibitors-induced Skin Disorders in the UK (2018–2030)

Table 37: Total Number of Cases on EGFR inhibitors by Cancer Type in Japan (2018–2030)

Table 38: Total Cases of EGFR Inhibitors-induced Skin Disorders in Japan (2018–2030)

Table 39: Comparison of emerging drugs under development

Table 40: AC-701, Clinical Trial Description, 2021

Table 41: ATR-04, Clinical Trial Description, 2021

Table 42: Imsidolimab (ANB019), Clinical Trial Description, 2021

Table 43: LUT014, Clinical Trial Description, 2021

Table 44: Seven Major Market Size of EGFR Inhibitors-induced Skin Disorders in USD Million (2018–2030)

Table 45: The United States Market Size of EGFR Inhibitors-Induced Skin Disorders by therapies in USD Million (2018–2030)

Table 46: Key Market Forecast Assumptions for Imsidolimab (ANB019)

Table 47: The United States Market Size of EGFR Inhibitors-Induced Skin Disorders in USD Million (2018–2030)

Table 48: The United States Market Size of EGFR Inhibitors-Induced Skin Disorders by therapies in USD Million (2018–2030)

Table 49: Germany Market Size of EGFR Inhibitors-Induced Skin Disorders in USD Million (2018–2030)

Table 50: Germany Market Size of EGFR Inhibitors-Induced Skin Disorders by therapies in USD Million (2018–2030)

Table 51: France Market Size of EGFR Inhibitors-Induced Skin Disorders in USD Million (2018–2030)

Table 52: France Market Size of EGFR Inhibitors-Induced Skin Disorders by therapies in USD Million (2018–2030)

Table 53: Italy Market Size of EGFR Inhibitors-Induced Skin Disorders in USD Million (2018–2030)

Table 54: Italy Market Size of EGFR Inhibitors-Induced Skin Disorders by therapies in USD Million (2018–2030)

Table 55: Spain Market Size of EGFR Inhibitors-Induced Skin Disorders in USD Million (2018–2030)

Table 56: Spain Market Size of EGFR Inhibitors-Induced Skin Disorders by therapies in USD Million (2018–2030)

Table 57: The United Kingdom Market Size of EGFR Inhibitors-Induced Skin Disorders in USD Million (2018–2030)

Table 58: The United Kingdom Market Size of EGFR Inhibitors-Induced Skin Disorders by therapies in USD Million (2018–2030)

Table 59: Japan Market Size of EGFR Inhibitors-Induced Skin Disorders in USD Million (2018–2030)

Table 60: Japan Market Size of EGFR Inhibitors-Induced Skin Disorders by therapies in USD Million (2018–2030)

List of Figures

Figure 1: Principles of EGFR activation and inhibition

Figure 2: Mechanism of EGFR inhibitor-induced dermatological toxicity

Figure 3: Schematic representation of potential defects observed in the skin of EGFR inhibitors–treated patients

Figure 4: Current treatment options for EGFR inhibitor-associated symptoms

Figure 5: Total Cases of Cancer on EGFR Inhibitors in the 7MM (2018–2030)

Figure 6: Total Cases on EGFR Inhibitors in the 7MM (2018–2030)

Figure 7: Total Cases of EGFR Induced Skin Disorders in the 7MM (2018–2030)

Figure 8: Total Cases of EGFR Induced Skin Disorders by Cancer Type in the 7MM (2018–2030)

Figure 9: Total Number of Cases on EGFR inhibitors by Cancer Type in the United States (2018–2030)

Figure 10: Total Cases of EGFR Inhibitors-induced Skin Disorders in the United States (2018–2030)

Figure 11: Total Number of Cases on EGFR inhibitors by Cancer Type in Germany (2018–2030)

Figure 12: Total Cases of EGFR Inhibitors-induced Skin Disorders in Germany (2018–2030)

Figure 13: Total Number of Cases on EGFR inhibitors by Cancer Type in France (2018–2030)

Figure 14: Total Cases of EGFR Inhibitors-induced Skin Disorders in France (2018–2030)

Figure 15: Total Number of Cases on EGFR inhibitors by Cancer Type in Italy (2018–2030)

Figure 16: Total Cases of EGFR Inhibitors-induced Skin Disorders in Italy (2018–2030)

Figure 17: Total Number of Cases on EGFR inhibitors by Cancer Type in Spain (2018–2030)

Figure 18: Total Cases of EGFR Inhibitors-induced Skin Disorders in Spain (2018–2030)

Figure 19: Total Number of Cases on EGFR inhibitors by Cancer Type in the United Kingdom (2018–2030)

Figure 20: Total Cases of EGFR Inhibitors-induced Skin Disorders in the United Kingdom (2018–2030)

Figure 21: Total Number of Cases on EGFR inhibitors by Cancer Type in Japan (2018–2030)

Figure 22: Total Cases of EGFR Inhibitors-induced Skin Disorders in Japan (2018–2030)

Figure 23: Patient Journey

Figure 24: Seven Major Market Size of EGFR Inhibitors-induced Skin Disorders in USD Million (2018–2030)

Figure 25: Seven Major Market Size of EGFR Inhibitors-induced Skin Disorders by Therapies in USD Million (2018–2030)

Figure 26: Market Size of EGFR Inhibitors-Induced Skin Disorders in the United States, USD Million (2018–2030)

Figure 27: The United States Market Size of EGFR Inhibitors-Induced Skin Disorders by Therapies in USD Million (2018–2030)

Figure 28: Market Size of EGFR Inhibitors-Induced Skin Disorders in Germany, USD Million (2018–2030)

Figure 29: Germany Market Size of EGFR Inhibitors-Induced Skin Disorders by Therapies in USD Million (2018–2030)

Figure 30: Market Size of EGFR Inhibitors-Induced Skin Disorders in France, USD Million (2018–2030)

Figure 31: France Market Size of EGFR Inhibitors-Induced Skin Disorders by Therapies in USD Million (2018–2030)

Figure 32: Market Size of EGFR Inhibitors-Induced Skin Disorders in Italy, USD Million (2018–2030)

Figure 33: Italy Market Size of EGFR Inhibitors-Induced Skin Disorders by Therapies in USD Million (2018–2030)

Figure 34: Market Size of EGFR Inhibitors-Induced Skin Disorders in Spain, USD Million (2018–2030)

Figure 35: Spain Market Size of EGFR Inhibitors-Induced Skin Disorders by Therapies in USD Million (2018–2030)

Figure 36: Market Size of EGFR Inhibitors-Induced Skin Disorders in the United Kingdom, USD Million (2018–2030)

Figure 37: The UK Market Size of EGFR Inhibitors-Induced Skin Disorders by Therapies in USD Million (2018–2030)

Figure 38: Market Size of EGFR Inhibitors-Induced Skin Disorders in Japan, USD Million (2018–2030)

Figure 39: Japan Market Size of EGFR Inhibitors-Induced Skin Disorders by Therapies in USD Million (2018–2030)

Figure 40: Market Drivers

Figure 41: Market Barriers

Figure 42: SWOT Analysis

Figure 43: Unmet Needs

AstraZeneca

Pfizer

Novartis Pharmaceuticals

Janssen Research & Development

Yuhan Corporation/ Janssen Research & Development

Takeda

  • Tags:
  • EGFR Inhibitors-Induced Skin Disord...
  • Epidermal Growth Factor Receptor-E...
  • Epidermal Growth Factor Receptor-E...
  • Epidermal Growth Factor Receptor-E...
  • Epidermal Growth Factor Receptor-E...
  • Epidermal Growth Factor Receptor-E...
  • Epidermal Growth Factor Receptor-E...
  • Epidermal Growth Factor Receptor-E...
  • Epidermal Growth Factor Receptor-E...
  • Epidermal Growth Factor Receptor-E...
  • Epidermal Growth Factor Receptor-E...
  • Epidermal Growth Factor Receptor-E...

Forward to Friend

Need A Quote